Physician profile
Robert A Causey
NPI 1255521175
$2,138.90
in general payments reported to CMS, 2019-2025
23 companies · $117 in 2025
The $117 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2020: $163 · 2021: $28.60 · 2022: $231 · 2023: $552 · 2024: $238 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $309.80 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.16 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Alexion Pharmaceuticals, INC. | $234.97 | 2022-2024 | Ultomiris |
| Galderma Laboratories, L.P. | $208.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $205.56 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $148.07 | 2019 | |
| Pfizer INC. | $143.60 | 2019-2024 | |
| Merz North America, INC. | $115.27 | 2023-2024 | Xeomin |
| Glaxosmithkline, LLC. | $67.49 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.17 | 2023-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $63.28 | 2020-2024 | Verquvo |
| Amgen INC. | $63.03 | 2020-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $48.69 | 2019-2022 | |
| Inari Medical, INC. | $37.09 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Melinta Therapeutics, LLC | $28.20 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $26.65 | 2019-2020 | |
| Shire North American Group INC | $26.47 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $20.92 | 2023 | |
| Smith+Nephew, INC. | $20.71 | 2022 | |
| Recordati_rare_diseases_inc. | $18.04 | 2023 | Panhematin |
| Astellas Pharma US INC | $17.78 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.89 | 2023 | Rebyota |
| Mallinckrodt Hospital Products INC. | $14.38 | 2024 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Causey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.